Lawrence F. Eichenfield

Guest Editor for the following articles:

Dec
2001
Vol. 20. No. 4

Tacrolimus and Pimecrolimus, Introduction

Lawrence F. Eichenfield, MD

A challenge in designing this issue of Seminars in Cutaneous Medicine and Surgery was to collect and present a state of the art assessment of our knowledge of these medications for dermatologic use, while acknowledging that our communal experience with them is still fairly limited.

MORE
Dec
2001
Vol. 20. No. 4

Pathophysiologic Mechanisms in Atopic Dermatitis

Donald YM Leung, PhD | Mark Boguniewicz, MD

This article examines theĀ  pathophysiologic mechanisms involved in atopic dermatitis. An understanding of these mechanisms is critical for developing new treatment strategies for this increasingly common illness.

MORE
Dec
2001
Vol. 20. No. 4

Pimecrolimus (Elidel, SDZ ASM 981)– Preclinical Pharmacologic Profile and Skin Selectivity

Anton Stuetz, PhD | Maximillian Grassberger, PhD | Josef G Meingassner, DVM

The ascomycin macrolactam derivative pimecrolimus (Elidel, SDZ ASM 981; Novartis Pharma AG, Basel Switzerland) is a cell-selective inhibitor of inflammatory cytokines specifically developed for the treatment of inflammatory skin diseases, such as atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and plaque-type psoriasis.

MORE